Clinical Trial Detail

NCT ID NCT04381832
Title Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Arcus Biosciences, Inc.
Indications

prostate cancer

Therapies

AB928 + Enzalutamide + GLS-010

AB928 + Docetaxel + GLS-010

AB680 + AB928 + GLS-010

AB680 + AB928

Enzalutamide

Docetaxel

AB928 + GLS-010

Age Groups: adult senior

No variant requirements are available.